Laquinimod is an oral, once-daily CNS-active immunomodulator which can treat inflammation and neurodegeneration in MS.
The study, BRAVO demonstrated that laquinimod reduced annualized relapse rates (ARR), besides showing a reduction in the risk of disability progression.
The safety and tolerability profile of laquinimod was also favorable.